It has been recently shown in triple-negative breast cancer (TNBC) cells that inhibition of XPO1/CRM1 by selinexor represses survivin transcription by inhibiting STAT3 acetylation [22]. Here, STAT3 is linked to triple-negative breast carcinoma.